Acne drug at centre of ‘first’ IPR ruling of its kind

11-12-2014

Acne drug at centre of ‘first’ IPR ruling of its kind

vita khorzhevska / Shutterstock.com

Pharmaceutical company Supernus and its subsidiary Galderma have had their Oracea (doxycycline) acne treatment drug protected from a generic challenge, in a decision dubbed the “first of its kind”.


Supernus, Galderma, Amneal, Oracea, PTAB, USPTO

LSIPR